Pipeline

Project Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Regulatory Approval
Motixafortide (BL-8040) Stem Cell Mobilization
Pancreatic cancer
AML
AGI-134 Solid tumors

Motixafortide (BL-8040)

Motixafortide targets CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human ...

INDICATIONS : 3

CLINICAL STUDIES : 12

AGI-134

AGI-134 is a synthetic alpha-Gal glycolipid in development for solid tumors that is highly differentiated from other cancer ...

INDICATIONS : 1

CLINICAL STUDIES : 1